Mathew Shanley | Authors


Phase III Trial Needed to Confirm Clinical Benefit of Cabozantinib in Carcinoid and Pancreatic NETs

October 20, 2017

Encouraging results are being seen following the administration of cabozantinib (Cabometyx) in patients with carcinoid and pancreatic neuroendocrine tumors. Clinical benefit of the drug has been exhibited in patients enrolled in a prospective phase II trial, which was initiated in July 2012; however, a randomized phase III trial will be necessary for confirmation.